Patrik Strömberg

Patrik Strömberg has a diverse work experience spanning over a period of two decades. In their current position as Chief Executive Officer at AnaCardio, they began in September 2021. Prior to that, they served as a Board Member at Strike Pharma AB since May 2021.

From 2009 to 2021, Strömberg held various roles at Sobi - Swedish Orphan Biovitrum AB (publ). These positions included Vice President in External Innovation, Search & Evaluation until October 2021, Senior Director in Corporate Development from September 2018 to January 2021, Senior Director and Head of Biomedical Science & Portfolio Innovation from August 2015 to September 2018, Principal Scientist in Nonclinical Safety and Pharmacology from September 2011 to July 2015, and Project Leader from February 2009 to September 2014.

Prior to their time at Sobi, Strömberg worked as a Senior Scientist (Enzymology) at Biovitrum from September 2007 to January 2009, and as a Senior Scientist at AstraZeneca from October 2002 to September 2007.

Throughout their career, Strömberg has had various responsibilities, including project management, development of biopharmaceuticals, and evaluation of external innovation opportunities.

Patrik Strömberg has a strong educational background in the field of biochemistry and biomedicine. Patrik earned their Master's Degree in Biomedicine from Karolinska Institutet in 1999. Later, they pursued a Doctor of Philosophy (Ph.D.) degree in Biochemistry from the same institution, completing it in 2002. In 2013, Strömberg further expanded their education by obtaining a Master of Business Administration (M.B.A.) degree from Stockholm University, although the field of study for this degree is not specified.